Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 308.71 USD -0.02% Market Closed
Market Cap: 40.3B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+7%
Revenue
Forecast
+29%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

ALNY Price Targets Summary
Alnylam Pharmaceuticals Inc

Wall Street analysts forecast ALNY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALNY is 330.33 USD with a low forecast of 214.12 USD and a high forecast of 525 USD.

ALNY Lowest Forecast
Wall Street Target
214.12 USD
31% Downside
ALNY Average Forecast
Wall Street Target
330.33 USD
7% Upside
ALNY Highest Forecast
Wall Street Target
525 USD
70% Upside
Lowest
Price Target
214.12 USD
31% Downside
Average
Price Target
330.33 USD
7% Upside
Highest
Price Target
525 USD
70% Upside
Alnylam Pharmaceuticals Inc Competitors:
Price Targets
INMB
INmune Bio Inc
247% Upside
S
688293
Shanghai OPM Biosciences Co Ltd
44% Upside
FGEN
FibroGen Inc
73% Upside
W
300142
Walvax Biotechnology Co Ltd
16% Downside
INMB
INmune Bio Inc
247% Upside
S
688293
Shanghai OPM Biosciences Co Ltd
44% Upside
FGEN
FibroGen Inc
73% Upside
W
300142
Walvax Biotechnology Co Ltd
16% Downside
ADMA
ADMA Biologics Inc
59% Upside
1801
Innovent Biologics Inc
20% Downside
CRSP
CRISPR Therapeutics AG
89% Upside
068270
Celltrion Inc
41% Upside

Revenue
Forecast

Revenue Estimate
Alnylam Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Alnylam Pharmaceuticals Inc's revenue is 62%. The projected CAGR for the next 3 years is 29%.

62%
Past Growth
29%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Alnylam Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Alnylam Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

See Also

Summary
ALNY intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALNY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALNY stock valuation using valuation multiples.
Wall Street Estimates
ALNY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALNY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ALNY's stock price target?
Price Target
330.33 USD

According to Wall Street analysts, the average 1-year price target for ALNY is 330.33 USD with a low forecast of 214.12 USD and a high forecast of 525 USD.

What is Alnylam Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
29%

For the last 8 years the compound annual growth rate for Alnylam Pharmaceuticals Inc's revenue is 62%. The projected CAGR for the next 3 years is 29%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 262,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.